← HERON THERAPEUTICS, INC. /DE/
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($173.1m) | ($197.5m) | ($178.8m) | ($204.7m) | ($227.3m) | ($220.7m) | ($182.0m) | ($110.6m) | ($13.6m) | ($20.2m) | — | |
| Depreciation, Depletion and Amortization | $1.1m | $1.5m | $1.5m | $2.0m | $2.8m | $3.0m | $2.9m | $2.9m | $2.5m | $2.3m | $2.3m | |
| Depreciation | $1.1m | $1.5m | $1.5m | $2.0m | $2.8m | $3.0m | $2.9m | $2.9m | $2.5m | $2.3m | $2.3m | |
| Amortization of Debt Issuance Costs | — | — | — | — | — | $119k | $202k | $206k | $210k | $73k | — | |
| Share-based Payment Arrangement, Noncash Expense | $26.0m | $30.5m | $33.4m | $51.4m | $50.2m | $46.9m | $43.0m | $32.9m | $13.0m | $10.3m | $10.8m | |
| Share-based Payment Arrangement, Expense | $26.0m | $30.5m | $33.4m | $51.4m | $50.2m | $46.9m | $43.0m | $32.9m | $13.0m | $10.3m | $10.8m | |
| Nonoperating Income (Expense) | ($2.2m) | ($2.9m) | $5.1m | $5.9m | $885k | ($2.9m) | ($7.4m) | $56k | ($2.1m) | ($17.7m) | — | |
| Other Nonoperating Income (Expense) | $436k | ($38k) | $1.8m | $158k | ($847k) | ($878k) | ($6.5m) | $560k | $430k | $1.3m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $2.0m | $39.9m | $22.8m | ($24.8m) | $2.0m | ($6.4m) | $16.6m | $8.1m | $18.7m | $10.7m | ($5.0m) | |
| Increase (Decrease) in Inventories | $5.3m | $4.8m | $29.1m | ($14.1m) | $16.9m | $6.5m | $6.2m | ($12.5m) | $11.1m | $31.1m | ($27.4m) | |
| Increase (Decrease) in Accounts Payable | $3.5m | $12.0m | ($1.9m) | ($14.1m) | ($2.2m) | $3.3m | ($578k) | $15k | $8.5m | ($2.7m) | ($3.4m) | |
| Net Cash Provided by (Used in) Operating Activities | ($134.1m) |
($170.3m)
-27.00%
|
($191.8m)
-12.63%
|
($124.6m)
+35.05%
|
($184.8m)
-48.35%
|
($203.4m)
-10.03%
|
($146.9m)
+27.76%
|
($58.8m)
+59.98%
|
($22.5m)
+61.68%
|
($27.6m)
-22.47%
|
($20.3m)
+26.57%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $3.1m | $2.6m | $9.2m | $7.2m | $6.8m | $3.0m | $1.8m | $1.5m | $1.7m | $317k | ($599k) | |
| Gain (Loss) on Disposition of Property Plant Equipment | ($9k) | ($39k) | ($29k) | ($62k) | $847k | ($822k) | ($74k) | ($10k) | $27k | $98k | $11.8m | |
| Cash, Cash Equivalents, and Short-term Investments | $51.1m | $172.4m | $332.4m | $391.0m | $208.5m | $157.6m | $84.9m | $80.4m | $59.3m | $46.6m | — | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | $77k | $8k | $0 | $0 | $0 | $1k | $5k | $0 | — | |
| Net Cash Provided by (Used in) Investing Activities | $14.9m | $7.7m | ($278.6m) | ($21.8m) | $209.0m | $32.7m | ($3.3m) | $18.0m | $18.7m | $16.0m | $12.8m | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | — | $25.0m | $25.0m | — | — | — | — | — | — | — | ($150.0m) | |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | — | — | — | ($11.3m) | — | |
| Proceeds from Issuance of Common Stock | — | $306.3m | $363.1m | $162.2m | — | — | $75.1m | $29.8m | — | $18.3m | $18.3m | |
| Net Cash Provided by (Used in) Financing Activities | $57.5m |
$293.7m
+411.24%
|
$357.6m
+21.75%
|
$186.4m
-47.87%
|
$9.1m
-95.12%
|
$156.0m
+1613.65%
|
$75.1m
-51.89%
|
$54.1m
-27.91%
|
$940k
-98.26%
|
$14.4m
+1434.79%
|
$14.3m
-0.80%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($61.8m) | $131.2m | ($112.7m) | $40.1m | $33.2m | ($14.6m) | ($75.2m) | $13.3m | ($2.9m) | $2.8m | $26.1m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | $71.9m | $105.1m | $90.5m | $15.4m | $28.7m | $25.8m | $28.6m | $26.1m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $6.7m | $11.5m | $18.3m | $22.2m | $6.8m | — | — | — | — | — | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $1.6m | $2.8m | $1.2m | — | — | $1.2m | $2.2m | $3.1m | $4.9m | $6.5m | — | |
| Additional Financial Items | ||||||||||||
| General and Administrative Expense | $21.4m | $25.6m | $29.3m | $37.9m | $42.2m | $40.2m | $37.4m | $49.0m | $53.4m | $54.6m | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $6.0m | $9.6m | — | |
| Investment Income, Interest | — | $1.0m | $6.0m | $7.3m | $3.6m | $433k | $1.6m | $3.4m | $3.5m | $1.9m | — | |
| Operating Expenses | $172.2m | $225.3m | $261.4m | — | — | — | — | — | — | — | — | |
| Operating Lease, Expense | — | — | — | $3.1m | $3.9m | $3.7m | $2.8m | $2.9m | $3.0m | $3.1m | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | $77.5m | $146.0m | $88.6m | $86.3m | $107.7m | $127.0m | $144.3m | $154.9m | — |